• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

BioMarin Pharmaceutical (BMRN)

Common Shares
Sell: $59.44|Buy: $61.50|Change: 0.02 (0.03%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.

Address

770 Lindaro Street
San Rafael
CA
USA
94901

Telephone

+1 415 455-7558

Website

https://www.biomarin.com

Sector 

Healthcare

Forecast key dates

NameKey Date
BioMarin Pharmaceutical Inc Third Quarter Earnings Conference Call for 20262026-10-27T16:30:00
BioMarin Pharmaceutical Inc Third Quarter Earnings Results for 20262026-10-27T00:00:00
BioMarin Pharmaceutical Inc Second Quarter Earnings Conference Call for 20262026-08-04T16:30:00
BioMarin Pharmaceutical Inc Second Quarter Earnings Results for 20262026-08-04T00:00:00
Biomarin Pharmaceutical Inc Annual General Meeting for 20262026-05-20T09:00:00
Biomarin Pharmaceutical Inc First Quarter Earnings Conference Call for 20262026-05-01T16:30:00
Biomarin Pharmaceutical Inc First Quarter Earnings Results for 20262026-05-01T00:00:00
Biomarin Pharmaceutical Inc Annual Report for 20252026-02-24T00:00:00
Biomarin Pharmaceutical Inc Fourth Quarter Earnings Conference Call for 20252026-02-19T16:30:00
Biomarin Pharmaceutical Inc Fourth Quarter Earnings Results for 20252026-02-19T00:00:00

Previous key dates

NameKey Date
BioMarin Pharmaceutical Inc. Business Update2025-12-19T08:15:00
Jefferies Global Healthcare Conference2025-11-18T10:30:00
BioMarin Pharmaceutical Inc Third Quarter Earnings Conference Call for 20252025-10-27T16:30:00
BioMarin Pharmaceutical Inc Third Quarter Earnings Result for 20252025-10-27T00:00:00
Morgan Stanley Global Healthcare Conference2025-09-09T11:30:00
Wells Fargo Healthcare Conference2025-09-04T08:45:00
Cantor Global Healthcare Conference2025-09-03T08:00:00
BioMarin Pharmaceutical Inc Second Quarter Earnings Conference Call for 20252025-08-04T16:30:00
BioMarin Pharmaceutical Inc Second Quarter Earnings Results for 20252025-08-04T00:00:00
Biomarin Pharmaceutical Inc Annual General Meeting for 20252025-05-20T09:00:00
Acquisition of Inozyme Pharma2025-05-16T00:00:00
Biomarin Pharmaceutical Inc First Quarter Earnings Conference Call for 20252025-05-01T16:30:00
Biomarin Pharmaceutical Inc First Quarter Earnings Result for 20252025-05-01T00:00:00
TD Cowen 45th Annual Healthcare Conference2025-03-04T06:50:00
Biomarin Pharmaceutical Inc Annual Report for 20242025-02-24T00:00:00
Biomarin Pharmaceutical Inc Fourth Quarter Earnings Conference Call for 20242025-02-19T16:30:00
Biomarin Pharmaceutical Inc Fourth Quarter Earnings Result for 20242025-02-19T00:00:00
43rd Annual J.P. Morgan Healthcare Conference2025-01-13T12:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.